Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Clinical Trials Related to Talquetamab
Related studies linked through entity extraction aliases.
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Status
- RECRUITING
- Phase
- PHASE2
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Status
- RECRUITING
- Phase
- PHASE2
The Norwegian Immunotherapy in Multiple Myeloma Study
- Status
- RECRUITING
- Phase
- N/A
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Status
- RECRUITING
- Phase
- PHASE2
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Status
- RECRUITING
- Phase
- PHASE3
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2